Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119228, Singapore; Translational Laboratory in Genetic Medicine, 8A Biomedical Grove, Immunos, Level 5, Singapore, 138648, Singapore.
Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria, 3800, Australia.
Pharmacol Res. 2020 Aug;158:104685. doi: 10.1016/j.phrs.2020.104685. Epub 2020 Feb 22.
Over the last two decades, developments in nanomedicine have resulted in technical advances with application to clinical science. Both organic and inorganic nanoparticles (NPs) have shown tolerability, pharmacologic specificity and biodegradability. A subclass of NPs, protein NPs, have garnered recent attention due to the inherent biocompatibility of protein substrates. Protein NPs are currently being employed widely in pharmaceuticals development with applications in nasal, pulmonary, intravenous, ocular and oral delivery. Despite the distinct advantages of orally administered pharmaceuticals, the development of oral delivery systems has been comparatively limited. Therefore, this review attempts to discuss the most recent experimental and pre-clinical findings in the development of protein NPs for oral delivery, while envisioning upcoming challenges.
在过去的二十年中，纳米医学的发展带来了应用于临床科学的技术进步。有机和无机纳米颗粒（NPs）都显示出了耐受性、药理特异性和生物降解性。由于蛋白质基质的固有生物相容性，一类 NPs，即蛋白质 NPs，最近引起了人们的关注。蛋白质 NPs 目前正在广泛应用于药物开发中，可用于鼻腔、肺部、静脉、眼部和口服给药。尽管口服药物具有明显的优势，但口服递药系统的发展相对有限。因此，本文试图讨论口服递药用蛋白质 NPs 的最新实验和临床前研究结果，并展望未来的挑战。
